Neuland Laboratories Ltd
NSE: NEULANDLAB BSE: 524558
₹13509
(3.68)%
Mon, 09 Feb 2026, 07:52 am
Market Cap167.25B
PE Ratio72.17
Dividend0.09
Health Technology
Pharmaceuticals: Major
24.5Kneuland laboratories ltd History
1984
- Neuland Laboratories Limited was incorporated as a private limited company.
1986
- The company commenced operations at its plant at Bonthapally Village, Medak District, Andhra Pradesh.
1988
- Neuland Drugs & Pharmaceuticals Private Limited was incorporated.
1990
- The company expanded its installed capacity for salbutamol sulphate and its intermediates to 9 tpa.
1992
- The company entered into an agreement with Indian Institute of Chemical Technology for process know-how for the manufacture of Ketorolac Tromethamine and Enalapril Maleate on December 2nd.
1993
- The company completed a project for the manufacture of terbutaline sulphate, labetalol hydrochloride, and expanded the capacity of salbutamol sulphate to 18 tpa.
- Neuland Drugs & Pharmaceuticals Private Limited was merged with Neuland Laboratories Limited as per the Scheme of Amalgamation approved by the High Court of Andhra Pradesh.
1994
- The company completed a project for further diversifying its bulk drug manufacture and set up a new plant at I.D.A. Pashamylaram, Medak district, Andhra Pradesh.
- Commercial production commenced in October 1994.
- The company's equity issue of Rs.870 lacs was oversubscribed 70 times and the shares are listed on the Hyderabad and Bombay Stock Exchanges.
2009
- Ms. Deepika Gupta joined as Company Secretary and compliance officer of the company.
2012
- Neuland Laboratories Ltd issued rights in the ratio of 5:12.
- The registered office of the company was shifted to Sanali Info park, 'A' Block, Ground floor,8-2-120/113, Road No.2, Banajara Hills, Hyderabad- 500034.
2013
- The board recommended a dividend of Rs. 1.20 per share of a face value of Rs. 10 each.
- Neuland Labs received the 2013 CMO Leadership Award for Regulatory Excellence.
2014
- Neuland Labs inaugurated a new manufacturing facility constructed for its collaboration with Mitsubishi Healthcare Unit API Corporation.
- The board recommended a dividend of 30% at Rs. 3 per equity share on a face value of Rs. 10 each.
- Neuland Laboratories announced rights in the ratio of 4:25.
2016
- The company entered into a Joint Development Agreement with Phoenix Embassy Techno Zone Private Limited.
2017
- Neuland Labs completed the acquisition of an API plant.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800